Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy
- PMID: 19655176
- DOI: 10.1007/s00520-009-0708-1
Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy
Abstract
Purpose: Knowledge of oral mucositis (OM) in patients with acute leukemia (AL) and chemotherapy (CT) has remained limited. Thus, a prospective, longitudinal study was undertaken to characterize clinical features, associated risk factors, and behavior of OM in a cohort of AL patients starting CT.
Methods: Prospective and longitudinal study. A cohort of patients, older than 15 years of age with AL, scheduled to receive CT, was followed from March 2006 to October 2007. At baseline and three times per week, for 21 days, patients had an oral examination performed using the Oral Mucositis Assessment Scale (OMAS); also, oral pain and difficulty to swallow were recorded using a visual analog scale. Weekly, salivary flow measurements (Schirmer's test modified version) were done.
Results: A cohort of 29 AL patients was followed for a median time of 21 (range, 14-53) days; 12 (41.4%) developed OM, with a mean OMAS score of 0.181 (SD +/- 0.56) and a mean peak OMAS score of 1.8 (SD +/- 0.56). The OM onset mean time was 9.8 (range, 2-20, SD +/- 6.09) days, with a mean duration of 7 (range, 3-14, SD +/- 4.15) days. OM was significantly correlated with salivary flow [rs = 0.420 (P = 0.0051)], oral pain [rs = 0.47 (P < 0.0001)], ability to swallow [rs = 0.36 (P = 0.0001)], and type of food intake [rs = 0.38 (P < 0.0001)].
Conclusions: OM is a frequent and early side effect of CT closely correlated with oral pain, difficulty to swallow, and impairment in food intake.
Similar articles
-
Double-blind placebo-controlled randomized clinical trial evaluating doxycycline effects on chemotherapy-induced oral mucositis.J Clin Pharm Ther. 2018 Apr;43(2):202-208. doi: 10.1111/jcpt.12633. Epub 2017 Sep 25. J Clin Pharm Ther. 2018. PMID: 28948645 Clinical Trial.
-
Oral mucositis: a phenomenological study of pediatric patients' and their parents' perspectives and experiences.Support Care Cancer. 2009 Jul;17(7):829-37. doi: 10.1007/s00520-009-0618-2. Epub 2009 Mar 26. Support Care Cancer. 2009. PMID: 19322593
-
Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life.Support Care Cancer. 2010 Nov;18(11):1477-85. doi: 10.1007/s00520-009-0771-7. Epub 2009 Nov 15. Support Care Cancer. 2010. PMID: 19916030
-
Case-control study analyzing the relationship between oral microcirculation and oral mucositis and pain in patients under antineoplastic therapy.Lasers Med Sci. 2023 May 8;38(1):118. doi: 10.1007/s10103-023-03777-3. Lasers Med Sci. 2023. PMID: 37154854
-
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients.Oral Dis. 2017 Oct;23(7):941-948. doi: 10.1111/odi.12677. Epub 2017 May 16. Oral Dis. 2017. PMID: 28403570
Cited by
-
Telmisartan Modulates the Oral Mucositis Induced by 5-Fluorouracil in Hamsters.Front Physiol. 2018 Aug 29;9:1204. doi: 10.3389/fphys.2018.01204. eCollection 2018. Front Physiol. 2018. PMID: 30210365 Free PMC article.
-
Serum amylase level as a predictive biomarker for persistent grade 1 chemotherapy-associated oral mucositis: a retrospective cross-sectional study.Int J Clin Oncol. 2025 Jun;30(6):1098-1108. doi: 10.1007/s10147-025-02749-7. Epub 2025 Apr 3. Int J Clin Oncol. 2025. PMID: 40180763
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical